Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

A Structural and Functional Role for Disulfide Bonds in a Class II Hydrophobin.

Sallada ND, Dunn KJ, Berger BW.

Biochemistry. 2018 Feb 6;57(5):645-653. doi: 10.1021/acs.biochem.7b01166. Epub 2018 Jan 9.

PMID:
29277996
2.

Enzymatic biomineralization of biocompatible CuInS2, (CuInZn)S2 and CuInS2/ZnS core/shell nanocrystals for bioimaging.

Spangler LC, Chu R, Lu L, Kiely CJ, Berger BW, McIntosh S.

Nanoscale. 2017 Jul 13;9(27):9340-9351. doi: 10.1039/c7nr02852k.

PMID:
28661538
3.

Single Enzyme Direct Biomineralization of CdSe and CdSe-CdS Core-Shell Quantum Dots.

Yang Z, Lu L, Kiely CJ, Berger BW, McIntosh S.

ACS Appl Mater Interfaces. 2017 Apr 19;9(15):13430-13439. doi: 10.1021/acsami.7b00133. Epub 2017 Apr 5.

PMID:
28358193
4.

Direct Single-Enzyme Biomineralization of Catalytically Active Ceria and Ceria-Zirconia Nanocrystals.

Curran CD, Lu L, Jia Y, Kiely CJ, Berger BW, McIntosh S.

ACS Nano. 2017 Mar 28;11(3):3337-3346. doi: 10.1021/acsnano.7b00696. Epub 2017 Feb 21.

PMID:
28212489
5.

A Secreted Ankyrin-Repeat Protein from Clinical Stenotrophomonas maltophilia Isolates Disrupts Actin Cytoskeletal Structure.

MacDonald LC, O'Keefe S, Parnes MF, MacDonald H, Stretz L, Templer SJ, Wong EL, Berger BW.

ACS Infect Dis. 2016 Jan 8;2(1):62-70. doi: 10.1021/acsinfecdis.5b00103. Epub 2015 Nov 5.

PMID:
27622948
6.

Interplay of Specific Trans- and Juxtamembrane Interfaces in Plexin A3 Dimerization and Signal Transduction.

Barton R, Khakbaz P, Bera I, Klauda JB, Iovine MK, Berger BW.

Biochemistry. 2016 Sep 6;55(35):4928-38. doi: 10.1021/acs.biochem.6b00517. Epub 2016 Aug 24.

PMID:
27508400
7.

A specific, transmembrane interface regulates fibroblast activation protein (FAP) homodimerization, trafficking and exopeptidase activity.

Wonganu B, Berger BW.

Biochim Biophys Acta. 2016 Aug;1858(8):1876-82. doi: 10.1016/j.bbamem.2016.05.001. Epub 2016 May 4.

8.

Single-enzyme biomineralization of cadmium sulfide nanocrystals with controlled optical properties.

Dunleavy R, Lu L, Kiely CJ, McIntosh S, Berger BW.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):5275-80. doi: 10.1073/pnas.1523633113. Epub 2016 Apr 26.

9.

Engineering broad-spectrum digestion of polyuronides from an exolytic polysaccharide lyase.

MacDonald LC, Weiler EB, Berger BW.

Biotechnol Biofuels. 2016 Feb 24;9:43. doi: 10.1186/s13068-016-0455-8. eCollection 2016.

10.

Cysteines in the neuropilin-2 MAM domain modulate receptor homooligomerization and signal transduction.

Barton R, Driscoll A, Flores S, Mudbhari D, Collins T, Iovine MK, Berger BW.

Biopolymers. 2015 Jul;104(4):371-8. doi: 10.1002/bip.22619.

PMID:
25656526
11.

A cytosolic juxtamembrane interface modulates plexin A3 oligomerization and signal transduction.

Barton R, Palacio D, Iovine MK, Berger BW.

PLoS One. 2015 Jan 7;10(1):e0116368. doi: 10.1371/journal.pone.0116368. eCollection 2015.

12.

Evolution of invasion in a diverse set of Fusobacterium species.

Manson McGuire A, Cochrane K, Griggs AD, Haas BJ, Abeel T, Zeng Q, Nice JB, MacDonald H, Birren BW, Berger BW, Allen-Vercoe E, Earl AM.

MBio. 2014 Nov 4;5(6):e01864. doi: 10.1128/mBio.01864-14.

13.

Membrane-enabled dimerization of the intrinsically disordered cytoplasmic domain of ADAM10.

Deng W, Cho S, Su PC, Berger BW, Li R.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15987-92. doi: 10.1073/pnas.1409354111. Epub 2014 Oct 27.

14.

Insight into the role of substrate-binding residues in conferring substrate specificity for the multifunctional polysaccharide lyase Smlt1473.

MacDonald LC, Berger BW.

J Biol Chem. 2014 Jun 27;289(26):18022-32. doi: 10.1074/jbc.M114.571299. Epub 2014 May 7.

15.

A polysaccharide lyase from Stenotrophomonas maltophilia with a unique, pH-regulated substrate specificity.

MacDonald LC, Berger BW.

J Biol Chem. 2014 Jan 3;289(1):312-25. doi: 10.1074/jbc.M113.489195. Epub 2013 Nov 20.

16.

A novel assay for assessing juxtamembrane and transmembrane domain interactions important for receptor heterodimerization.

Su PC, Berger BW.

J Mol Biol. 2013 Nov 15;425(22):4652-8. doi: 10.1016/j.jmb.2013.07.022. Epub 2013 Jul 20.

PMID:
23876708
17.

Atypical erythema migrans in patients with PCR-positive Lyme disease.

Schutzer SE, Berger BW, Krueger JG, Eshoo MW, Ecker DJ, Aucott JN.

Emerg Infect Dis. 2013 May;19(5):815-7. doi: 10.3201/eid1905.120796. No abstract available.

18.

High-yield membrane protein expression from E. coli using an engineered outer membrane protein F fusion.

Su PC, Si W, Baker DL, Berger BW.

Protein Sci. 2013 Apr;22(4):434-43. doi: 10.1002/pro.2224. Epub 2013 Feb 21.

19.

Identifying key juxtamembrane interactions in cell membranes using AraC-based transcriptional reporter assay (AraTM).

Su PC, Berger BW.

J Biol Chem. 2012 Sep 7;287(37):31515-26. doi: 10.1074/jbc.M112.396895. Epub 2012 Jul 22.

20.

Consensus motif for integrin transmembrane helix association.

Berger BW, Kulp DW, Span LM, DeGrado JL, Billings PC, Senes A, Bennett JS, DeGrado WF.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):703-8. doi: 10.1073/pnas.0910873107. Epub 2009 Dec 18.

21.

The structure and function of platelet integrins.

Bennett JS, Berger BW, Billings PC.

J Thromb Haemost. 2009 Jul;7 Suppl 1:200-5. doi: 10.1111/j.1538-7836.2009.03378.x. Review.

22.

Protein-protein interactions in the membrane: sequence, structural, and biological motifs.

Moore DT, Berger BW, DeGrado WF.

Structure. 2008 Jul;16(7):991-1001. doi: 10.1016/j.str.2008.05.007. Review.

23.

Computational design of peptides that target transmembrane helices.

Yin H, Slusky JS, Berger BW, Walters RS, Vilaire G, Litvinov RI, Lear JD, Caputo GA, Bennett JS, DeGrado WF.

Science. 2007 Mar 30;315(5820):1817-22.

24.

Effects of additives on surfactant phase behavior relevant to bacteriorhodopsin crystallization.

Berger BW, Gendron CM, Lenhoff AM, Kaler EW.

Protein Sci. 2006 Dec;15(12):2682-96. Epub 2006 Nov 6.

25.

The role of protein and surfactant interactions in membrane-protein crystallization.

Berger BW, Gendron CM, Robinson CR, Kaler EW, Lenhoff AM.

Acta Crystallogr D Biol Crystallogr. 2005 Jun;61(Pt 6):724-30. Epub 2005 May 26.

PMID:
15930629
26.

Relating surfactant properties to activity and solubilization of the human adenosine a3 receptor.

Berger BW, García RY, Lenhoff AM, Kaler EW, Robinson CR.

Biophys J. 2005 Jul;89(1):452-64. Epub 2005 Apr 22.

27.

Predictive crystallization of ribonuclease A via rapid screening of osmotic second virial coefficients.

Tessier PM, Johnson HR, Pazhianur R, Berger BW, Prentice JL, Bahnson BJ, Sandler SI, Lenhoff AM.

Proteins. 2003 Feb 1;50(2):303-11.

PMID:
12486724
28.

Self-interaction chromatography: a novel screening method for rational protein crystallization.

Tessier PM, Vandrey SD, Berger BW, Pazhianur R, Sandler SI, Lenhoff AM.

Acta Crystallogr D Biol Crystallogr. 2002 Oct;58(Pt 10 Pt 1):1531-5. Epub 2002 Sep 26.

PMID:
12351855
29.

Picosecond time-resolved fluorescence from blue-emitting chromophore variants Y66F and Y66H of the green fluorescent protein.

Kummer AD, Wiehler J, Schüttrigkeit TA, Berger BW, Steipe B, Michel-Beyerle ME.

Chembiochem. 2002 Jul 2;3(7):659-63.

PMID:
12325000
30.

A first-tier rapid assay for the serodiagnosis of Borrelia burgdorferi infection.

Gomes-Solecki MJ, Wormser GP, Persing DH, Berger BW, Glass JD, Yang X, Dattwyler RJ.

Arch Intern Med. 2001 Sep 10;161(16):2015-20.

PMID:
11525704
31.

Infection with multiple strains of Borrelia burgdorferi sensu stricto in patients with Lyme disease.

Seinost G, Golde WT, Berger BW, Dunn JJ, Qiu D, Dunkin DS, Dykhuizen DE, Luft BJ, Dattwyler RJ.

Arch Dermatol. 1999 Nov;135(11):1329-33.

PMID:
10566830
32.

Current aspects of Lyme disease and other Borrelia burgdorferi infections.

Berger BW.

Dermatol Clin. 1997 Apr;15(2):247-55. Review.

PMID:
9098634
33.

Bloodstream invasion in early Lyme disease: results from a prospective, controlled, blinded study using the polymerase chain reaction.

Goodman JL, Bradley JF, Ross AE, Goellner P, Lagus A, Vitale B, Berger BW, Luger S, Johnson RC.

Am J Med. 1995 Jul;99(1):6-12. Erratum in: Am J Med. 1996 Aug;101(2):239.

PMID:
7598144
34.

Cultivation of Borrelia burgdorferi from human tick bite sites: a guide to the risk of infection.

Berger BW, Johnson RC, Kodner C, Coleman L.

J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):184-7.

PMID:
7829700
35.
36.

Laboratory tests for Lyme disease.

Berger BW.

Dermatol Clin. 1994 Jan;12(1):19-24. Review.

PMID:
8143381
37.

Lyme disease.

Berger BW.

Semin Dermatol. 1993 Dec;12(4):357-62. Review.

PMID:
8312152
38.

Erythema migrans.

Berger BW.

Clin Dermatol. 1993 Jul-Sep;11(3):359-62. Review. No abstract available.

PMID:
8221516
39.

Lyme disease.

Berger BW, Lesser RL.

Dermatol Clin. 1992 Oct;10(4):763-75. Review.

PMID:
1395157
40.

Erythema migrans in Lyme disease: a correction.

Berger BW.

JAMA. 1992 Aug 19;268(7):874. No abstract available.

PMID:
1640613
41.

Failure of Borrelia burgdorferi to survive in the skin of patients with antibiotic-treated Lyme disease.

Berger BW, Johnson RC, Kodner C, Coleman L.

J Am Acad Dermatol. 1992 Jul;27(1):34-7.

PMID:
1619074
42.

Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin.

Berger BW, Johnson RC, Kodner C, Coleman L.

J Clin Microbiol. 1992 Feb;30(2):359-61.

43.

Antibiotic treatment for pregnant victims of Lyme disease.

Berger BW.

J Am Acad Dermatol. 1991 Apr;24(4):663. No abstract available.

PMID:
1867693
44.

Clinical implications of delayed growth of the Lyme borreliosis spirochete, Borrelia burgdorferi.

MacDonald AB, Berger BW, Schwan TG.

Acta Trop. 1990 Dec;48(2):89-94.

PMID:
1980573
45.

Clinical and microbiologic findings in six patients with erythema migrans of Lyme disease.

Berger BW, Johnson RC.

J Am Acad Dermatol. 1989 Dec;21(6):1188-91. Erratum in: J Am Acad Dermatol 1990 Mar;22(3):483.

PMID:
2511231
46.

Cutaneous manifestations of Lyme borreliosis.

Berger BW.

Rheum Dis Clin North Am. 1989 Nov;15(4):627-34. Review.

PMID:
2685922
47.

Dermatologic manifestations of Lyme disease.

Berger BW.

Rev Infect Dis. 1989 Sep-Oct;11 Suppl 6:S1475-81.

PMID:
2814169
48.

Use of an autologous antigen in the serologic testing of patients with erythema migrans of Lyme disease.

Berger BW, MacDonald AB, Benach JL.

J Am Acad Dermatol. 1988 Jun;18(6):1243-6.

PMID:
3290287
49.

Treatment of erythema chronicum migrans of Lyme disease.

Berger BW.

Ann N Y Acad Sci. 1988;539:346-51.

PMID:
3190102
50.

Treating erythema chronicum migrans of Lyme disease.

Berger BW.

J Am Acad Dermatol. 1986 Sep;15(3):459-63.

PMID:
3093544

Supplemental Content

Loading ...
Support Center